GENSCRIPT BIO(HK:01548) GUOTAI HAITONG SECURITIES·2025-11-21 12:51Investment Rating - The report maintains a "Buy" rating for King’s Ray Biotechnology, with a target price of HKD 26.21 per share [9][13]. Core Insights - King’s Ray Biotechnology focuses on a "technology-driven" and "global layout" strategy, aiming for long-term revenue growth and clear growth paths across its business segments [2][9]. - The company has set a long-term revenue target of USD 3 billion by 2035, with an operating profit margin exceeding 20% [9]. - The report highlights the company's strategic positioning as a leading global supplier of biopharmaceutical services and products, including antibody drugs and gene & cell therapies [9]. Financial Summary - Total revenue projections for 2023 to 2027 are as follows: USD 840 million in 2023, USD 594 million in 2024, USD 939 million in 2025, USD 825 million in 2026, and USD 961 million in 2027, with growth rates of 34.2%, -29.2%, 58.0%, -12.1%, and 16.4% respectively [4][10]. - Gross profit is expected to increase from USD 410 million in 2023 to USD 441 million in 2027, while net profit is projected to rise significantly from a loss of USD 95 million in 2023 to a profit of USD 155 million in 2027 [4][10]. - The report anticipates a significant increase in net profit in 2024 to USD 2,962 million, followed by a decrease in 2025 and a gradual recovery thereafter [4][10]. Business Strategy - The company aims to solidify its cash flow to support its life sciences, biopharmaceutical CRDMO, and synthetic biology segments, driving profitability growth [9]. - King’s Ray plans to enhance its core competitiveness in antibody protein business and expand into non-outsourced markets, providing innovative instruments and solutions [9]. - The report emphasizes the integration of business capabilities to transform mature services into one-stop solutions, accelerating productization and growth [9].